April 8, 2026
Onco-Innovations Limited
ISIN: CA68237C1059
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
Company also announces Marketing Engagement Vancouver, Canada – April 7, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce...
Read more >>Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Vancouver, Canada – February 4, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announces that it has filed a preliminary base...
Read more >Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
Vancouver, Canada – December 07, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) (“Onco” or the “Company”) is pleased to announce that it has engaged...
Read more >Onco-Innovations Attends University of Alberta’s 2025 Innovation Awards
Vancouver, Canada – November 25, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) ("Onco" or the "Company") is pleased to announce that it was invited to...
Read more >Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies
Vancouver, Canada – November 20, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that its manufacturing partner,...
Read more >Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development
Vancouver, Canada – November 18, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that it is initiating...
Read more >